SinuSys CEO Thomas Schreck and CMO Dr. Jerome Hester tell MassDevice.com how they hope to replace sinus surgery with a simple, in-office procedure and how a doctor and his patient formed a company together.
Tom Roberts, CEO of San Antonio, Texas-based startup Invictus Medical discusses the company's approach to preventing the cranial deformation plagiocephaly, also known as flattening of the skull, that affects up to 30% of newborns.
Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.
A MassDevice.com analysis of reported payments for the medical device tax last year finds that 14 companies accounted for more than 97% of the nearly $500 million collected.
The financial impact of the medical device tax appears to be much lower than originally feared, a MassDevice.com analysis shows, with the medtech industry paying at least $500 million on the 2.3% levy last year.
The medical device tax levied as part of Obamacare is neither the overwhelming burden it's portrayed to be by the medtech industry, nor the benign contribution toward healthcare reform its advocates describe. Instead, it's the worst of both worlds.
When President Barack Obama signed the Patient Protection & Affordable Care Act into law back in 2010, he set the stage for a controversy within a low-profile industry that eventually drew some high-profile attention: A 2.3% tax on U.S. sales of medical devices.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Researchers supported by the National Institutes of Health are launching a clinical trial to test a device that uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus, a persistent buzzing or ringing sound in the ears in the absence of any real sound.
The small clinical trial, which is recruiting volunteers, is being conducted at four centers through a cooperative agreement with MicroTransponder, Inc., a medical device company based in Dallas.